Once hailed as an anti-aging magic bullet, telomerase has failed to live up to the hype as it was profiled in a 1998 Los ...

Eisai and Biogen’s reign at the top of the Alzheimer’s disease market may be short lived. | Eisai and Biogen’s reign at the ...

Thanks to respiratory syncytial virus (RSV) shot Arexvy’s new label expansion into a slightly younger pool of adults, GSK is ...

A new antitrust investigation in Italy has ensnared Novartis, Genentech, Biogen and Samsung Bioepis for allegedly colluding ...

After fessing up to wire fraud charges, a former Takeda employee will be preparing for a sentencing hearing rather than ...

The Biotechnology Innovation Organization, under the new leadership of CEO John Crowley, recently backed the BIOSECURE Act.

AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer ...

In response, Vanda argued that the Future Pak offer "significantly" undervalued the company. To ward off the unwanted ...

Seven years after buying land in Des Plaines, Illinois, that housed a Salvation Army campus, German CDMO Vetter Pharma is ...

Deerfield Agency has opened its wallet again, buying up healthcare marketing and advertising firm Embedded to further extend ...

The IL-23 inhibitor Skyrizi, first approved in 2019 by the FDA, brought in $7.7 billion in sales last year, itself a jump of ...

On the eve of the American Society of Clinical Oncology’s annual meeting last week, a piece of news set off vigorous ...